Novo Nordisk
2011-12-22T08:37:00Z
2011-12-22T08:37:00Z
Novo Nordisk files for regulatory approval of the ultra-long-acting insulin Degludec in Japan
Novo Nordisk today announced the submission to the Japanese Pharmaceuticals and Medical Devices Agency, PMDA, of a new drug application for the approval of ultra-long-acting insulin Degludec. This new-generation basal insulin has been developed for the treatment of people with type 1 and type 2 diabetes.
Further information:
| Media: | Investors: |
| Katrine Sperling | Klaus Bülow Davidsen |
| Tel: (+45) 4442 6718 | Tel: (+45) 4442 3176 |
| krsp@novonordisk.com | klda@novonordisk.com |
| Frank Daniel Mersebach | |
| Tel: (+45) 4442 0604 | |
| fdni@novonordisk.com | |
| Lars Borup Jacobsen | |
| Tel: (+45) 3075 3479 | |
| lbpj@novonordisk.com | |
| In North America: | |
| Ken Inchausti | Jannick Lindegaard |
| Tel: (+1) 609 514 8316 | Tel: (+1) 609 786 4575 |
| kiau@novonordisk.com | jlis@novonordisk.com |
Company Announcement no 80 / 2011